Business
Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy
Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced that it has signed a Memorandum of Understanding, subject to the execution of a definitive agreement and satisfaction of customary closing conditions, to establish a dedicated subsidiary for the research, development, and commercialization of the Company's technology for the treatment of Parkinson's disease.
About this update from Matricelf Ltd.
[{"type":"text","content":"NESS ZIONA, Israel, March 3, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced that it has signed a Memorandum of Understanding, subject to the execution of a definitive agreement and satisfaction of customary closing conditions, to establish a dedicated subsidiary for the research, development, and commercialization of the Company's technology for the treatment of Parkinson's disease.","length":492,"tagName":"p"},{"type":"text","content":"The agreement follows the Company's January 27, 2026 announcement regarding preliminary non binding discussions on this initiative. The subsidiary will focus on applying Matricelf's proprietary autologous cell and tissue engineering platform to Parkinson's disease and Parkinsonism indications.","length":306,"tagName":"p"},{"type":"text","content":"Strategic Rationale","length":19,"tagName":"p"},{"type":"text","content":"The establishment of a dedicated subsidiary is designed to enable focused managerial attention, capital allocation, and development strategy for the Parkinson's indication, while allowing the parent company to maintain strategic and economic exposure to the program.","length":270,"tagName":"p"},{"type":"text","content":"This structure is intended to facilitate dedicated capital raising at the subsidiary level without requiring equity issuance at the parent company level. Matricelf is expected to retain a significant equity stake alongside defined revenue participation mechanisms, potentially creating long term value for shareholders.","length":319,"tagName":"p"},{"type":"text","content":"Overview of Parkinson's Disease Market Opportunity","length":54,"tagName":"p"},{"type":"text","content":"Parkinson's disease is a progressive neurodegenerative brain disorder characterized primarily by motor symptoms such as tremor, bradykinesia, and rigidity, as well as non motor symptoms including sleep disturbances, pain, and cognitive changes. There is currently no cure, and treatments focus on symptom management.","length":320,"tagName":"p"},{"type":"text","content":"According to the World Health Organization, the prevalence of Parkinson's disease has doubled over the past 25 years, with more than 8.5 million people living with the condition worldwide as of 20...